Intellectual Property India Publishes Patent Application for 'Anti-Cd3 Antibodies And Methods For Their Use' Filed by Adanate, Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517090948 A) filed by Adanate, Inc., San Mateo, U.S.A., on Sept. 23, for 'anti-cd3 antibodies and methods for their use.'

Inventor(s) include Shellooe, Raymond; Sissons, James; and Ebens, Allen.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to novel anti-CD3 antibodies (as monoclonal antibodies or as used in other formats, such as bispecific or multi-specific formats) and compositions comprising such antibodies or cells activated, by such antibodies for use in treating disorders associated with CD3, such as human cancer therapy."

The patent application was internationally filed on Feb. 22, 2024, under International application No.PCT/US2024/016863.

Disclaimer: Curated by HT Syndication.